Menovo(SH:603538) Ge Long Hui·2026-02-12 08:40Core Viewpoint - Meihua announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., participated in the national centralized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] - The procurement is part of the continuation of the national centralized procurement for drugs from batches 1-8, with results expected to be implemented by the end of March 2026 [1] Group 2: Financial Impact - The total sales for the ten selected products are projected to be 71.75 million yuan for the first three quarters of 2025, accounting for 6.4% of the company's total revenue during the same period [1] - The number of selected products represents 40% of the total products in the formulation segment of the company [1] Group 3: Procurement Cycle - The procurement cycle for the selected drugs will run from the actual execution date of the selection results until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle and ensure the completion of the agreed procurement volume [1]